Antigen News and Research

RSS

Oxford COVID-19 vaccine trials move to stage 3 human trials

The technical name of the vaccine is ChAdOx1 nCoV-19 (AZD1222), as it is made from a virus called ChAdOx1, which is a weakened and non-replicating version of a common cold virus (adenovirus). The vaccine has been engineered to express the SARS-CoV-2 spike protein.

5 Jul 2020

Research suggests protective effect of influenza vaccine against COVID-19 severity and mortality

A new study involving over 92,000 patients with COVID-19 in Brazil shows that the odds of severe disease, ventilatory support requirement, and death are reduced with a recent trivalent flu vaccine. This seems to indicate that these vaccines should be used as widely as possible to reduce the risk of severe COVID-19, especially among high-risk groups. The study is published on the preprint server medRxiv* in June 2020.

5 Jul 2020

Pfizer/BioNTech COVID-19 vaccine shows promise - virus neutralizing antibodies achieved

In a recent medRxiv* paper, a research group from the U.S. and Germany showed a robust immunogenic response and a promising safety profile of the novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) – actively encouraging its accelerated clinical development and potential rapid production.

2 Jul 2020

Tiny balls of minerals are better vehicles for promising mRNA-based therapy

University of Wisconsin-Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination -- including a COVID-19 vaccine from Moderna Therapeutics that has advanced to clinical trials with humans.

2 Jul 2020

Developing Vaccines and Therapeutics by Exploiting Structure in Spherical Nucleic Acids

An interview discussing the use of spherical nucleic acids (SNAs) and what they show about the importance of structure in pharmaceutical development.

From Pittcon 2 Jul 2020

Novavax SARS-CoV-2 vaccine candidate shows promise in animal models

A new study published on the preprint server bioRxiv in June 2020 shows that a candidate spike protein vaccine can induce neutralizing antibodies, antiviral T cell responses, and protection against infection.

2 Jul 2020

New NCCN guidelines explain how to recognize and manage immunotherapy-related side effects

The National Comprehensive Cancer Network today announced the completion of the new NCCN Guidelines for Patients®: Immunotherapy Side Effects series, with the publication of a book focused on chimeric antigen receptor (CAR) T-cell therapy. This closely follows the publication of a separate book on immune checkpoint inhibitors, both created with support from the NCCN Foundation®.

1 Jul 2020

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field.

1 Jul 2020

Striking CryoEM image of SARS-CoV-2

A new study by researchers from the UK and Germany and published on the preprint server bioRxiv in June 2020 reports the results of a detailed study of the S protein on the intact virus, using cryoelectron microscopy (cryoEM) and tomography. This could help understand the conformation of the S protein on the virion and how it interacts with neutralizing antibodies.

30 Jun 2020

Modified Vaccinia Ankara-based vaccine candidate for SARS-CoV-2

Now, a new study by researchers at Emory University, the University of Texas Medical Branch and the Ragon Institute and published on the preprint server bioRxiv in June 2020 reports the development of a promising new vaccine candidate that may rapidly and effectively induce the production of neutralizing antibodies against the spike protein of the virus.

30 Jun 2020

Genomics used to trace origin of SARS-CoV-2 in Canada

A new study published in June 2020 on the preprint server bioRxiv discusses the use of phylogenetic analysis to trace the origin of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and its spread into and then within Canada. The study findings may help optimize public health policies in the case of future outbreaks.

28 Jun 2020

BATM provides business and trading update

BATM, a leading provider of real-time technologies for networking solutions and medical laboratory systems, provides the following business and trading update.

26 Jun 2020

Berkeley Lights announces Opto™ antigen-presenting bead kit to accelerate the expansion of antigen-specific T cells used to develop cell-based therapies

Berkeley Lights, Inc. today announced the Opto Antigen-Presenting Bead kit, a new reagent kit that activates and expands antigen-specific T cells in blood.

From Bruker Cellular Analysis 25 Jun 2020

Study assesses impact of anti-SARS-CoV-2 convalescent plasma in COVID-19 disease

The current COVID-19 pandemic is still very much active in most parts of the world. In the absence of effective antiviral drugs or vaccines, scientists are studying the use of blood plasma from convalescent COVID-19 patients, banking on its neutralizing antibody content.

25 Jun 2020

Avacta provides update on COVID-19 rapid antigen test development partnership with Cytiva

Avacta Group plc is pleased to announce that the rapid test strips to detect SARS-COV-2 spike protein have been evaluated by Avacta’s partners at Cytiva.

From Cytiva Life Sciences 24 Jun 2020

Antibodies against prevalent endemic human coronaviruses may provide cross-protection to SARS-CoV-2

Researchers from Qatar have demonstrated that antibody repertoires against endemic human coronaviruses are qualitatively different in children when compared to the general adult population, as well as healthy adult blood bank donors – and they may also provide cross-protection against epidemic/pandemic strains.

23 Jun 2020

Pangolin version of SARS-CoV-2 can cause COVID-19-like illness

The results of a recent multinational research endeavor, currently available on the bioRxiv preprint server, display the biological framework of SARS-CoV-2-related coronavirus in pangolins and reveal striking similarities to coronavirus disease (COVID-19) in humans, but also show that it can be transmitted vertically to the fetus.

23 Jun 2020

Producing CAR T cell therapy at a lower cost

Chimeric antigen receptor (CAR) T cell therapy is a new and in some cases highly effective form of immunotherapy to treat certain types of cancer of the blood and lymph system.

23 Jun 2020

Single-dose Israeli vaccine candidate protective against SARS-CoV-2

Now, a new Israeli study published on the preprint server bioRxiv in June 2020 reports a new recombinant vaccine expressing the S or spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be highly protective with a single dose in an animal model. This could be a gamechanger in the fight to contain the outbreak.

23 Jun 2020

Innovative use of focused ultrasound shows promise against glioblastoma

An innovative use of focused ultrasound being pioneered at the University of Virginia School of Medicine is showing promise against glioblastoma, the deadliest brain tumor, and could prove useful against other difficult-to-treat cancers.

22 Jun 2020

Antigen News and Research

Oxford COVID-19 vaccine trials move to stage 3 human trials

Research suggests protective effect of influenza vaccine against COVID-19 severity and mortality

Pfizer/BioNTech COVID-19 vaccine shows promise - virus neutralizing antibodies achieved

Tiny balls of minerals are better vehicles for promising mRNA-based therapy

Developing Vaccines and Therapeutics by Exploiting Structure in Spherical Nucleic Acids

Novavax SARS-CoV-2 vaccine candidate shows promise in animal models

New NCCN guidelines explain how to recognize and manage immunotherapy-related side effects

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Striking CryoEM image of SARS-CoV-2

Modified Vaccinia Ankara-based vaccine candidate for SARS-CoV-2

Genomics used to trace origin of SARS-CoV-2 in Canada

BATM provides business and trading update

Berkeley Lights announces Opto™ antigen-presenting bead kit to accelerate the expansion of antigen-specific T cells used to develop cell-based therapies

Study assesses impact of anti-SARS-CoV-2 convalescent plasma in COVID-19 disease

Avacta provides update on COVID-19 rapid antigen test development partnership with Cytiva

Antibodies against prevalent endemic human coronaviruses may provide cross-protection to SARS-CoV-2

Pangolin version of SARS-CoV-2 can cause COVID-19-like illness

Producing CAR T cell therapy at a lower cost

Single-dose Israeli vaccine candidate protective against SARS-CoV-2

Innovative use of focused ultrasound shows promise against glioblastoma

Changing the landscape of R&D to build clinical success from the ground up

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Latest Life Science News